MERZ-AESTHETICS
21.3.2024 09:01:28 CET | Business Wire | Press release
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, is presenting new data for its product portfolio in addition to perspectives on medical aesthetics trends at the 2024 Aesthetic and Anti-Aging Medicine World Congress. AMWC is a leading global scientific conference specializing in aesthetic and anti-aging medicine. Participants can attend live in Monaco or tune in virtually beginning March 27 through March 29, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321775430/en/
Merz Aesthetics’ programming includes a sponsored symposium on March 28 from 14:00 - 16:00 CET, Beauty Without Borders: Aesthetics Across Continents, moderated by Dr. Sabrina Fabi, featuring commentary from Dr. Kate Goldie, Dr. Siew Tuck Wah, Dr. Rolf Bartsch and Dr. Rossana Vasconcelos. During the session, the group will discuss the multifaceted landscape of beauty and aging around the world, the nuances and variances of aging concerns among different patient populations and the recommended techniques and products.
“Each year, AMWC allows us the opportunity to connect and collaborate with peers from around the world and provides a forum to showcase our research and advancements in medical aesthetics,” said Terri Phillips, MD, Chief Medical Affairs Officer, Merz Aesthetics. “We’re excited to engage in scientific exchange, foster new connections and discuss innovations within our portfolio, in addition to sharing insights from the evolving field of regenerative aesthetics.”
“At Merz Aesthetics, we aim to provide the best experience possible for our health care professionals and their patients,” said Gonzalo Mibelli, President, EMEA, Merz Aesthetics. “I’m looking forward to presenting our latest data and honoring the commitment we’ve made to our customers to meet their evolving needs.”
In addition to the symposium, Merz Aesthetics is presenting five e-posters for the first time. The abstracts will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts. Following are the highlighted e-posters:
- Long-term Duration and Safety of CaHA(+)-CMC for the Treatment of Jawline – Jeremy B. Green, MD, Roberta Del Campo, MD, Alan J. Durkin, MD, David K. Funt, MD, Nicole Nasrallah, MS, Keith Martinez, PhD, Amir Moradi, MD
- Tissue Integration of Hyaluronic Acid-Containing Dermal Fillers: Automated Approach Using a Human Skin Model Under Optimal Tension – Kay Marquardt, PhD, Christian Hartmann, PhD, Michael Conneely, PhD, Robyn Hickerson, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
- Stimulation of Elastin Neogenesis by Micro-Focused Ultrasound (MFU-V) – Kay Marquardt, PhD, Christian Hartmann, PhD, Flora Wegener, PhD, Nils Warfving, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
- Consensus Agreements on Regenerative Aesthetics: Terminology, Goals, and Strategies – Dr. Kate Goldie, Dr. Greg Chernoff, Dr. Niamh Corduff, Dr. Owen Davies, Dr. Jani van Loghem, Dr. Bianca Viscomi
- Micro-focused Ultrasound with Visualization and Aesthetic Outcomes: A Systematic Review and Meta-analysis of Clinical Studies – Dr. Sabrina Guillen Fabi, Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Julia Sevi, Dr. Julieta Spada, Dr. Vasanop Vachiramon, Dr. Rossana Vasconcelos, Dr. Siew Tuck Wah
Merz Aesthetics will be located at Booth J1 on Level 1.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321775430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom